Final selection of the 3rd face-to-face evaluation of the Big3 innovation growth support project by the Ministry of SMEs and Startups

The uniqueness and innovation that only the source technology of Anyfusion made possible to automate anticancer preparations and, last Thursday, we were given an opportunity as the last speaker, and we ended the presentation with confidence based on our technological superiority.

And the, We received a final selection notice today. Thanks to the officials of the Ministry of SMEs and Startups.

The anticancer drug market is a rapidly growing market with a high growth rate of 20% per year.

The market size in 2019 is 6 trillion won, including the CSTD, an auxiliary adapter adopted by only 28 countries, and the robot market, which is 1.1 billion won per unit as a partial preparation.

I is predicted to grow to 8 trillion won due to COVID-19 in this year.

Compared to CSTD and Robot, ACPi Anyfusion Pro is a technology that allows one pharmacist to fully automate more than 300 cases per day. The labor costs of high-paid pharmacists are drastically reduced for poor anticancer drug preparation work. We will develop ACPi Anyfusion Pro, an automated anticancer drug dispenser that guarantees complete safety for both the pharmacists and the patient.

As soon as possible starting product development and finishing clinical and certification by next year, we will do our best to achieve the historical task of establishing itself as a representative medical device in Korea by changing the market paradigm such as blood transfusion, precision medicine injection, and anticancer drug preparation with the innovative Anyfusion technology.

Thank you.